A Tailored Approach
Finding a Treatment That Fits Your Patient
Table of Contents
- Salvage therapy post pomalidomide-based regimen in relapsed/ refractory myeloma.
(Fouquet G, et al. ASH 2015:1831)
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
(Usmani SZ, et al. ASH 2015:29)
- Management of infusion-related reactions following daratumumab in patients with ≥3 lines of therapy or double refractory multiple myeloma: MMY2002 (SIRIUS).
(Voorhees P, et al. ASH 2015:1829)
- Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (GEN503 study).
(Plesner T, et al. ASH 2015:507)
- Results from the international, randomized phase III study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naïve CLL/SLL (RESONATETM-2).
(Tedeschi A, et al. ASH 2015:495)
- Investigator Commentary – An Interview with Dr. Alessandra Tedeschi on the RESONATETM-2 Trial.
- Rituximab in combination with bendamustine or chlorambucil for the treatment of CLL: primary results from the randomized phase IIIb MaBLe study.
(Michallet AS, et al. iwCLL 2015:178)
- Investigator Commentary – An Interview with Dr. Veronique Leblond on the MaBLe Study.
- Canadian Perspective – A Canadian Perspective by Dr. Carolyn Owen on the MaBLe study that compared bendamustine plus rituximab to chlorambucil plus rituximab in the management of unfit CLL patients.
- CLL2-BIG – A novel treatment regimen of bendamustine followed by GA101 and ibrutinib followed by ibrutinib and GA101 maintenance in patients with CLL: interim results of a phase II trial.
(von Tresckow J, et al. ASH 2015:4151)
- Safety and efficacy of obinutuzumab plus bendamustine in previously untreated patients with CLL: subgroup analysis of the GREEN study.
(Stilgenbauer S, et al. ASH 2015:493)
- Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: results of a phase III randomized double-blind placebo-controlled study.
(Zelenetz AD, et al. ASH 2015:LBA-5)
- Insights into the management of adverse events in patients with previously treated CLL/SLL: experience from the phase III HELIOS study of ibrutinib combined with bendamustine/rituximab.
(Chanan-Khan A, et al. ASH 2015:2936)
- Impact of high-risk prognostic parameters and addition of ibrutinib to bendamustine/rituximab on outcomes for patients with relapsed CLL/SLL from the phase III double-blind HELIOS trial.
(Chanan-Khan A, et al. ASH 2015:1732)
- Ibrutinib plus bendamustine/rituximab (BR) is associated with greater reductions in fatigue than placebo plus BR among patients with relapsed/refractory CLL and fatigue.
(Traina S, et al. ASH 2015:267)
- Comparing single-agent ibrutinib, bendamustine plus rituximab (BR) and ibrutinib plus BR in patients with previously treated CLL/SLL: An indirect comparison of the RESONATE™ and HELIOS trials.
(Hillmen P, et al. ASH 2015:2944)
- Outcome of ibrutinib treatment by baseline genetic features in patients with relapsed or refractory CLL/SLL with del(17p) in the RESONATE™-17 study.
(Stilgenbauer S, et al. ASH 2015:833)
- Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL.
(O’Brien SM, et al. ASH 2015:1747)
- Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities.
(Lampson BL, et al. ASH 2015:497)
- Outcomes of patients with CLL after discontinuing idelalisib.
(Barrientos JC, et al. ASH 2015:4155)
- Preliminary results of a phase II, open-label study of venetoclax monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy.
(Jones J, et al. ASH 2015:715)
- Real-world results on ibrutinib in patients with relapsed or refractory CLL: Data from 95 Swedish patients treated in a compassionate use program.
(Hansson L, et al. ASH 2015:1745)
- Comparison of phase III ibrutinib results versus standard of care in Sweden in patients with relapsed/refractory (R/R) CLL.
(Österborg A, et al. ASH 2015:1751)
- Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: a population-based retrospective cohort study of administrative medical claims data in the U.S..
(Barrientos JC, et al. ASH 2015:3301)
- Atrial fibrillation in patients with CLL/SLL on ibrutinib.
(Farooqui M, et al. ASH 2015:2933)
- Atrial fibrillation in patients with chronic lymphocytic leukemia.
(Shanafelt T, et al. ASH 2015:2950)
- High sensitivity testing shows multiclonal mutations in patients with CLL treated with BTK inhibitor and lack of mutations in ibrutinib-naïve patients.
(Albitar A, et al. ASH 2015:716)
- Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in ibrutinib-treated patients with CLL.
(Kazianka L, et al. ASH 2015:718)
- Ibrutinib therapy increases BCL-2 dependence and enhances sensitivity to venetoclax in CLL.
(Deng J, et al. ASH 2015:490)
- Expert Commentary – A Commentary by Dr. Clemens-Martin Wendtner on Chemoimmunotherapy in CLL: The Evolving Role of This Standard of Care.
- Canadian Perspective – A Canadian Perspective by Dr. Graeme Fraser on managing patients with CLL who are receiving ibrutinib treatment.
- Decreasing early deaths in APL by using a simplified treatment algorithm and establishing a network with academic and community centres.
(Jillella A, et al. ASH 2015:3779)
- Results of a phase III trial including arsenic trioxide consolidation for pediatric patients with APL: a report from the Children’s Oncology Group study AAML0631.
(Kutny MA, et al. ASH 2015:219)
- Ibrutinib versus temsirolimus: results from a phase III, international, randomized, open-label, multicentre study in patients with previously treated mantle-cell lymphoma.
(Rule S, et al. ASH 2015:469)
- Investigator Commentary – An Interview with Dr. Simon Rule on the MCL3001 (RAY) Trial.
- Canadian Perspective – A Canadian Perspective by Dr. Laurie Sehn on the RAY trial.
- Symptom data from a phase III, international, randomized, open-label, multicentre study in patients with previously-treated MCL treated with ibrutinib versus temsirolimus.
(Hess G, et al. ASH 2015:1542)
- Primary results of the health-related quality of life assessment from the phase III GADOLIN study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma.
(Cheson BD, et al. ASH 2015:1532)
- Benda-EAM high-dose therapy prior to ASCT is effective in resistant or relapsed DLBCL.
(Isidori A, et al. ASH 2015:1999)
- Rituximab, bendamustine, and cytarabine as front-line therapy in mantle cell lymphoma: a single centre, retrospective study.
(Branca A, et al. ASH 2015:2710)
- Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma.
(Martin P, et al. ASH 2015:1543)
- Ibrutinib plus rituximab in treatment-naïve patients with follicular lymphoma: results from a multicentre, phase II study.
(Fowler NH, et al. ASH 2015:470)
- Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma.
(Ujjani CS, et al. ASH 2015:471)
- Activity of idelalisib in high-risk follicular lymphoma with early relapse following front-line immunochemotherapy.
(Gopal AK et al. ASH 2015:2744)
- Pattern of care in indolent non follicular lymphoma: a report from NF10 project, an international, prospective, observational study coordinated by the Fondazione Italiana Linfomi.
(Luminari S, et al. ASH 2015:2686)
- Long-term outcomes, secondary malignancies, and stem cell collection following bendamustine in patients with previously treated indolent non-Hodgkin lymphoma.
(Martin P, et al. ASH 2015:3961)
- Bendamustine for patients with indolent lymphoproliferative neoplasms – update of a meta-analysis of randomized controlled trials (RCT).
(Vidal L, et al. ASH 2015:3963)
- Interim results of a multi-cohort phase II study on the use of brentuximab vedotin in combination with dacarbazine or bendamustine for front-line treatment of Hodgkin lymphoma in patients aged 60 years and above.
(Yasenchak CA, et al. ASH 2015:587)
- Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma.
(LaCasce A, et al. ASH 2015:3982)
- Results from LUX-Lung 7, a phase IIb trial of afatinib versus gefitinib as first-line treatment for patients with advanced NSCLC with activating EGFR mutations.
(Park K, et al. ESMO Asia 2015:LBA2)
- Investigator Commentary – An Interview with Dr. Tony Mok, Dr. Barbara Melosky, and Dr. Sandy Sehdev on the LUX-Lung 7 Trial.
- Subgroup analysis by race in LUX-Lung 3 and 6: overall survival with afatinib versus chemotherapy in patients with NSCLC harbouring EGFR mutations.
(Wu YL, et al. ESMO Asia 2015:445P)
- Afatinib versus chemotherapy for EGFR mutation-positive patients with NSCLC aged ≥65 years: subgroup analyses of LUX-Lung 3 and LUX-Lung 6.
(Wu YL, et al. ESMO Asia 2015:446P)
- Development of skin rash within the first week is a potential surrogate marker of effect in afatinib for EGFR mutant-positive NSCLC.
(Bessho A, et al. ESMO Asia 2015:453P)
- Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic NSCLC harbouring the common EGFR mutations Del19 and/or L858R.
(Thongprasert S, et al. ESMO Asia 2015:477TiP)
- Phase Ib trial of afatinib and BI 836845 in advanced NSCLC.
(Tan D, et al. ESMO Asia 2015:479TiP)
- Clinical activity and safety of the EGFR mutant-specific inhibitor, BI 1482694, in patients with T790M-positive NSCLC.
(Lee J, et al. ESMO Asia 2015:425PD)
- Phase II study of BI 1482694 in patients with T790M-positive NSCLC after treatment with an EGFR TKI.
(Jänne PA, et al. ESMO Asia 2015:476TiP)
- A phase III, randomized trial of nivolumab versus docetaxel in advanced non-squamous NSCLC: subgroup analyses and patient reported outcomes.
(Horn L, et al. ESMO Asia 2015:417O)
- Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017.
(Reck M, et al. ESMO Asia 2015:460P)
- Phase II/III study of pembrolizumab versus docetaxel in PD-L1-positive NSCLC after platinum-based therapy.
(Herbst RS, et al. ESMO Asia 2015:LBA3)
- KEYNOTE-042: a randomized, open-label, phase III study of pembrolizumab versus platinum-based chemotherapy in PD-L1-positive NSCLC.
(Mok T, et al. ESMO Asia 2015:481TiP)
- Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001.
(Ahn M, et al. ESMO Asia 2015:459P)
- Data from Korean patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001.
(Lee J, et al. ESMO Asia 2015:461P)
Carolyn Owen, MD
Dr. Carolyn Owen completed postgraduate training in internal medicine and hematology at the University of Ottawa and the University of British Columbia, respectively, followed by a research fellowship in molecular genetics at Barts and the London School of Medicine and Dentistry in London, UK. Her research focused on familial myelodysplasia and acute myeloid leukemia. She is currently an Assistant Professor at the Foothills Medical Centre & Tom Baker Cancer Centre, and her clinical interests are low-grade lymphoma and chronic lymphocytic leukemia. She is also the local principal investigator in Calgary for several clinical trials in these areas.
Graeme Fraser, MD, MSc, FRCPC
Dr. Graeme Fraser graduated from the University of Western Ontario (UWO) and completed post-graduate training in Internal Medicine and Hematology at UWO and McMaster University, respectively. His training in malignant hematology was supported by a National Cancer Institute of Canada–Terry Fox Foundation Clinical Research Fellowship. Dr. Fraser is a hematologist at the Juravinski Cancer Centre/Hamilton Health Sciences in Hamilton, Ontario, and he is an Associate Professor in the Department of Oncology. His research interests include the care of adolescent and young adult cancer patients, clinical trials in chronic lymphocytic leukemia, lymphoma, and myeloma, and practice guideline development as a member of the Cancer Care Ontario Program in Evidence-Based Care.
Laurie H. Sehn, MD, MPH
Dr. Laurie H. Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of Lymphoma Canada (LC) since 2002 and is now Director of Research Fellowships for LC. Her research interests include the lymphoid cancers with particular focus on the biology and treatment of large-cell
lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.
Alessandra Tedeschi, MD
Dr. Alessandra Tedeschi obtained her medical degree from the University of Bologna, Italy and subsequently trained in hemato-oncology at the University of Ancona, Italy. She completed two research stages on lymphoproliferative disorders in the Department of Hematology at the Niguarda Hospital in Milan, Italy. Dr. Tedeschi has been a consultant in Hematology at the Niguarda Cancer Center, Niguarda Hospital in Milan, Italy since 1999. Her clinical work focuses on the treatment of patients with indolent lymphoproliferative disorders and her research interests include the study of chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia. Dr. Tedeschi is a principal and co-investigator on many national and international trials in CLL. She has published over 60 peer-reviewed research articles.
Veronique Leblond, MD
Dr. Veronique Leblond is a Professor and Head of the Department of Hematology at Pitié–Salpêtrière Hospital, Paris, France. She is the chair of the French Innovative Leukemia Group (FILO), focusing on acute leukemia, chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM), which includes more than 90 centres in France and Belgium. Dr. Leblond is responsible for a rare tumour network (K-VIROGREF) dedicated to the management of transplant recipients with virus-induced tumours, funded by the French National Cancer Institute (INCA) in 2012, and she is the head of GRECHY (Groupe de Recherche Clinique Hémopathie Lymphoïde) at the Pierre and Marie Curie University in Paris, France. She is also a member of the French Society of Hematology and the American Society of Hematology. Dr. Leblond was the principal investigator of several biological and clinical trials in WM and CLL. She received the Robert Kyle award in 2008 and the Waldenström award in 2012. Dr. Leblond is connected to several very active patient associations and charities including Laurette Fugain, SiLLC (Soutien et Information à la Leucémie Lymphoïde Chronique et la Maladie de Waldenström), International WM Foundation, and Waldenström France. She is an author of over 280 research articles, books, and book chapters.
Simon Rule, MD
Dr. Simon Rule is a Professor in Hematology at the Institute of Translational & Stratified Medicine, Plymouth University Peninsula Schools of Medicine & Dentistry, and a Hematologist at the Derriford Hospital in Plymouth, United Kingdom (UK). He has been a member of the National Cancer Research Network (NCRN) Lymphoma Committee since 2000 and serves as Chair of the NCRN Low Grade Lymphoma Clinical Studies Group. Dr. Rule’s clinical research interests are in non-Hodgkin lymphoma (NHL) and new drug development, with a specific interest in mantle cell lymphoma. Dr. Rule has been an author of over 70 publications in peer-reviewed journals. Over the last five years, Dr. Rule has been the Chief Investigator on 12 National studies and Principal Investigator on over 40 studies, mostly involving NHL. Within the UK, Dr. Rule runs all of the national clinical trials for mantle cell lymphoma.
Clemens-Martin Wendtner, MD
Dr. Clemens-Martin Wendtner is a Professor of Medicine and the Director of the Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine at the Klinikum Schwabing, Munich — an academic hospital of the University of Munich. He completed his MD at the University of Münster in 1993. Thereafter, he received postdoctoral training at the Max-Planck-Institute in Martinsried, Germany and at the National Institutes of Health (NIH) in Bethesda, U.S.A., until 1995. After a clinical fellowship at the University of Munich, he gained his German and U.S.A. licence (ECFMG) in Internal Medicine before specializing as a hematologist and oncologist at the same institution. Dr. Wendtner received his postdoctoral lecture qualification at the University of Munich in 2002, and since 2004, has been a full professor of Internal Medicine, Hematology, and Medical Oncology at the University of Cologne. Dr. Wendtner is a member of multiple national and international societies in the field of Medicine and has won several research awards, including first prize at the 6th International Symposium on Biological Therapy of Cancer in Munich, and a merit award from the American Society of Clinical Oncology. As a founding member of the German CLL Study Group (GCLLSG), he participates on the Steering Committee and is Secretary of the GCLLSG. He has been principal investigator for numerous phase I–III clinical studies, and his interests focus on the development of new therapies in the field of CLL.
Tony SK Mok, MD, FRCP(C), FRCP, FHKCP, FHKAM
Professor Tony Mok studied medicine at the University of Alberta and subsequently completed his fellowship training at the Princess Margaret Hospital in Toronto. After practising oncology and internal medicine for seven years in Toronto, he returned to Hong Kong in 1996 to pursue an academic career. Prof. Mok is a Li Shu Fan Medical Foundation Named Professor and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation. Prof. Mok is the Past President of the International Association for the Study of Lung Cancer (IASLC), Past Chair of the American Society of Clinical Oncology (ASCO) International Affairs Committee, a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO). Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is an Editor on Thoracic Oncology for the Journal of Clinical Oncology. He has also authored eight books in Chinese and hosted three television series in Hong Kong.
Barbara Melosky, MD, FRCP(C)
Dr. Barbara Melosky is a Clinical Associate Professor of Medicine at the University of British Columbia and a medical oncologist at the BC Cancer Agency in Vancouver. She graduated from medical school at the University of Manitoba, and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky is currently working in the fields of lung and gastrointestinal malignancies with a special interest in the side effects of targeted therapy. She sits on the Executive Committee for the Lung Disease Site NCIC Clinical Trials Group and is the annual Chair of the Canadian Lung Cancer Conference.
Sandeep Sehdev, MD
Dr. Sandeep Sehdev is an Assistant Professor (adjunct) at McMaster University in Hamilton and a medical oncologist serving the William Osler Health System in Brampton and Etobicoke and the Headwaters Healthcare Centre in Orangeville. He graduated from medical school at the University of Ottawa and completed a residency in oncology at the University of Toronto and Princess Margaret Hospital. Dr. Sehdev is currently a general community oncologist and continuing health education lead for oncology with a special interest in advocacy, community oncology and patient education, and applications of technology in learning. He has been involved in multiple multicentre clinical trials.